Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Blasts 5 Percent or More of Bone Marrow Nucleated Cells”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Early research (Phase 1)Ended earlyNCT03519984
What this trial is testing

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlasts 5 Percent or More of Bone Marrow Nucleated CellsMyelodysplastic/Myeloproliferative Neoplasm+8 more
University of Southern California 3
Early research (Phase 1)Study completedNCT02529813
What this trial is testing

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaBlasts 5 Percent or More of Bone Marrow Nucleated Cells+6 more
M.D. Anderson Cancer Center 26
Testing effectiveness (Phase 2)Ended earlyNCT03698552
What this trial is testing

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Blasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)WithdrawnNCT03851081
What this trial is testing

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT03801434
What this trial is testing

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Who this might be right for
BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated Cells+9 more
William Shomali 10
Early research (Phase 1)Looking for participantsNCT03896269
What this trial is testing

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Who this might be right for
Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 38